Dicerna Pharmaceuticals (DRNA) Stock Analysis

What Dicerna Pharmaceuticals does

Dicerna Pharmaceuticals, Inc. functions as a biopharmaceutical company primarily dedicated to the full spectrum of RNA interference (RNAi)-based drug development, from initial discovery to market commercialization. The firm leverages its exclusive GalXC RNAi platform to engineer therapeutic solutions for a diverse array of medical conditions. These include various liver-related ailments, spanning rare, cardiometabolic, viral, and chronic forms, alongside complement-mediated disorders, neurodegenerative diseases, and pain. Among its prominent development candidates are nedosiran, targeting primary hyperoxaluria; RG6346, designed for chronic hepatitis B virus infection; belcesiran, intended for deficiency-associated liver disease; and DCR-AUD, addressing alcohol use disorder. Dicerna has established significant collaborations with several leading pharmaceutical corporations, including Novo Nordisk A/S, F. Hoffmann-La Roche (both Ltd and Inc.), Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Founded in 2006 and based in Lexington, Massachusetts, Dicerna Pharmaceuticals, Inc. has been operating as a subsidiary of Novo Nordisk A/S since December 27, 2021.

Key metrics

ETFs linked to DRNA

Broad-market and Healthcare sector ETFs an investor holding Dicerna Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how DRNA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals trades under the ticker DRNA on NASDAQ.

Which exchange is DRNA listed on?

DRNA is listed on NASDAQ.

What sector does Dicerna Pharmaceuticals operate in?

Dicerna Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze DRNA in a portfolio?

PortView shows DRNA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.